Literature DB >> 20427497

Soluble human leukocyte antigen-g expression and glucose tolerance in subjects with different degrees of adiposity.

Anna Solini1, Elza Muscelli, Marina Stignani, Loredana Melchiorri, Eleonora Santini, Chiara Rossi, Brenno Domingues Astiarraga, Roberta Rizzo, Olavio Roberto Baricordi.   

Abstract

CONTEXT: Type 2 diabetes mellitus (T2DM) and obesity are characterized by a low-grade inflammation, which might be related to the development of insulin resistance. Human leukocyte antigen-G (HLA-G) shows antiinflammatory and tolerogenic properties, including the modulation of CD8+ T-cell cytotoxicity and regulation of CD4+ T-lymphocyte function. These functions are partially shared with IL-10, whose levels are reduced in insulin-resistant states.
OBJECTIVE: The aim was to explore the relationship between HLA-G and the metabolic and inflammatory pattern of obesity or T2DM. PATIENTS AND MAIN OUTCOME MEASURES: Soluble HLA-G, IL-6, and IL-10 were measured and related with metabolic and biochemical parameters in 230 volunteers with normal glucose tolerance, impaired glucose tolerance, or T2DM by oral glucose tolerance test.
RESULTS: sHLA-G, detected in 144 subjects (sHLA-G positive), was more frequent in T2DM or impaired glucose tolerance subjects than in normal glucose tolerance (chi(2) =18.6; P < 0.0001), and its plasma levels increased progressively across the classes of glucose tolerance. sHLA-G-positive individuals had higher body mass index, systolic blood pressure, and cholesterol levels; a reduced degree of insulin sensitivity; and almost 2-fold higher levels of IL-6, a cytokine related to insulin sensitivity, whereas IL-10 was similar. In the sHLA-G-positive subgroup, by a multivariate regression model, sHLA-G was significantly related to 2-h glucose, the area under insulin curve, and IL-6 levels (multiple r(2) = 0.14; P < 0.001), independently of age, gender, and body mass index.
CONCLUSIONS: A frequent expression of sHLA-G, linked to a typical biomarker of insulin resistance like IL-6, seems to characterize subjects with an impaired glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427497     DOI: 10.1210/jc.2009-2747

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Clinical Recommendations for the Use of Islet Cell Autoantibodies to Distinguish Autoimmune and Non-Autoimmune Gestational Diabetes.

Authors:  Kadri Haller-Kikkatalo; Raivo Uibo
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  The association between the HLA-G 14-bp insertion/deletion polymorphism and type 1 diabetes.

Authors:  H P V Silva; M A G Ururahy; K S C Souza; M B Loureiro; Y M C Oliveira; G H M Oliveira; A D Luchessi; K T C Carvalho; J C O C Freitas; E A Donadi; R D C Hirata; M G Almeida; R F Arrais; M H Hirata; A A Rezende
Journal:  Genes Immun       Date:  2015-10-22       Impact factor: 2.676

3.  The 14 bp Del/Ins HLA-G polymorphism is related with high blood pressure in acute coronary syndrome and type 2 diabetes mellitus.

Authors:  Ilian Janet García-González; Yeminia Valle; Fernando Rivas; Luis Eduardo Figuera-Villanueva; José Francisco Muñoz-Valle; Hector Enrique Flores-Salinas; Bianca Ethel Gutiérrez-Amavizca; Nory Omayra Dávalos-Rodríguez; Jorge Ramón Padilla-Gutiérrez
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

Review 4.  HLA-G Molecules in Autoimmune Diseases and Infections.

Authors:  Roberta Rizzo; Daria Bortolotti; Silvia Bolzani; Enrico Fainardi
Journal:  Front Immunol       Date:  2014-11-18       Impact factor: 7.561

5.  Evaluation of soluble human leukocyte antigen-G in peripheral blood of pregnant women with gestational diabetes mellitus.

Authors:  Saeide-Sadat Shobeiri; Saeid Abediankenari; Bahareh Lashtoo-Aghaee; Zahra Rahmani; Bahareh Esmaeili-Gorji
Journal:  Caspian J Intern Med       Date:  2016

Review 6.  The HLA-G Immune Checkpoint Plays a Pivotal Role in the Regulation of Immune Response in Autoimmune Diseases.

Authors:  Monika Zaborek-Łyczba; Jakub Łyczba; Paulina Mertowska; Sebastian Mertowski; Anna Hymos; Martyna Podgajna; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.